Altered p53 is associated with aggressive behavior of chondrosarcoma: A long term follow-up study

Cancer

Volumn 83, Issue 11, 1998, Pages 2324-2334

  Oshiro, Yumi ^a,b   Chaturvedi, Vijaya ^a   Hayden, Dorothy ^a   Nazeer, Tipu ^a   Johnson, Mark ^a   Johnston, Dennis A ^a   Ordóñez, Nelson G ^a   Ayala, Alberto G ^a   Czerniak, Bogdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Chondrosarcoma; Clinical behavior; Immunohistochemistry; P53; Sequencing

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHONDROSARCOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; CHONDROSARCOMA; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 0032402167     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U     Document Type: Article

References (33)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995;75: 203-10.
2. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818-31.
3. Kreicbergs A, Slezak E, Soderberg G. The prognostic significance of different histomorphologic features in chondrosarcoma. Virchows Arch A Pathol Anat 1981;390:1-10.
4. Ishida T, Kikuchi F, Machinami R. Histological grading and morphometric analysis of cartilaginous tumours. Virchows Arch A Pathol Anat 1991;418:149-55.
5. O'Neal LW, Ackerman LV. Chondrosarcoma of bone. Cancer 1951;551-77.
6. Unni KK, Dahlin DC. Grading of bone tumors. Semin Diagn Pathol 1984;1:165-72.
7. Alho A, Connor JF, Mankin HJ, Schiller AL, Campbell CJ. Assessment of malignancy of cartilage tumors using flow cytometry: a preliminary report. J Bone Joint Surg 1983;656A: 779-85.
8. Alho A, SkjedaJ S, Melvik JE, Pettersen EO, Larsen TE. The clinical importance of DNA synthesis and aneuploidy in bone and soft tissue tumors. Anticancer Res 1993;13:2383-7.
9. Coughlan B, Feliz A, Ishida T, Czerniak B, Dorfman HD. p53 expression and DNA ploidy of cartilage lesions. Hum Pathol 1995;26:620-4.
10. Helio H, Karaharju E, Bohling T, Kivioja A, Nordling S. Chondrosarcoma of bone: a clinical and DNA flow cytometric study. Ew J Surg Oncol 1995;21:408-13.
11. Kreicbergs A, Boquist L, Borssen B, Larsson SE. Prognostic factors in chondrosarcoma: a comparative study of cellular DNA content and clinicopathologic features. Cancer 1982; 50:577-83.
12. Mankin HJ, Connor JF, Schiller AL, Perlmutter N, Alho A, McGuire M. Grading of bone tumors by analysis of nuclear DNA content using flow cytometry. J Bone Joint Surg 1985; 67A:404-13.
13. Pritchard DJ, Lunke RJ, Taylor WF, Dahlin DC, Medley BE. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer 1980;45:149-57.
14. Mandahl N, Heim S, Arhedin K, Rydholm A, Willen H, Mitelman F. Chromosomal rearrangements in chondromatous tumors. Cancer 1990;65:242-8.
15. Ozisik YY, Meloni AM, Peier A, Altungoz O, Spanier SS, Zalupski MM, et al. Cytogenetic findings in 19 malignant bone tumors. Cancer 1994;74:2268-75.
16. Larramendy ML, Tarkkanen M, Valle J, Kivioja AH, Ervasti H, Karaharju E, et al. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 1997;150:685-91.
17. Jagasia AA, Block JA, Qureshi A, Diaz MO, Nobori T, Gitelis S, et al. Chromosome 9 related aberrations and deletions of the CDKNs and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett 1996;105:91-103.
18. Castresana JS, Barrios C, Gomez L, Kreicbergs A. Amplification of the c-myc protooncogene in human chondrosarcoma. Diagn Mol Pathol 1992;1:235-8.
19. Dobashi Y, Sugimura H, Sato A, Hirabayashi T, Kanda H, Kitagawa T, et al. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma. Diagn Mol Pathol 1993;2:257-63.
20. Hasegawa T, Seki K, Yang P, Hirose T, Hizawa K, Wada T, et al. Differentiation and proliferative activity in benign and malignant cartilage tumors of bone. Hum Pathol 1995;26: 838-45.
21. Nawa G, Ueda T, Mori S, Yoshikawa H, Fukuda H, Ishiguro S, et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 overexpression in chondrosarcomas. Int J Cancer 1996;69:86-91.
22. Simms WW, Ordonez NG, Johnston D, Ayala AG, Czerniak B. p53 expression in dedifferentiated chondrosarcoma. Cancer 1995;76:223-7.
23. Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, et al. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Res 1996;16:2009-15.
24. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54: 4855-78.
25. Schneider-Stock R, Radig K, Oda Y, Mellin W, Rys J, Niezabitowski A, et al. p53 gene mutations in soft-tissue sarcomas: correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol 1997;123:211-8.
26. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52: 6194-9.
27. Allred DC, Clard GM, Elledge R. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
28. Calzolari A, Chiarelli I, Bianchi S, Messerini L, Gallo O, Porfirio B, et al. Immunohistochemical vs. molecular biology methods: complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997;107:7-11.
29. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutations in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994;9:949-54.
30. Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP, Parfrey NA. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996;180:364-70.
31. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, et al. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 1995;6:S9-13.
32. Zheng W, Sung J, Cao P, Zhang ZF, Cai R, Godwin TA, et al. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol Oncol 1997;64:38-48.
33. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Bocker W, et al. Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 1993;119:172-8.